New hope for Hard-to-Treat lymphoma: experimental drug shows promise

NCT ID NCT05563844

Ongoing Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called purinostat mesylate in 74 adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer that has come back or not responded to treatment). The goal is to see if the drug can shrink tumors and control the disease, while also checking for side effects. Participants receive the drug by injection, and researchers measure how many people respond and for how long.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma interdigitating dendritic cell sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Contacts and locations

Show contact details

Locations

Ruijin Hospital of Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610000, China